Potential Benefits and Clinical Outcomes Using GLP-1 receptor agonists as an add-on therapy in type 1 diabetes offers several potential advantages, especially for patients with complex metabolic needs
From net deprescription and medication changes alone, cost savings were over $83,000 , or about $1700 per patient per year
These risks can be linked to changes in cortisol levels, a hormone that plays a critical role in the bodys response to stress and metabolism
The prevention of the glucagon rise might improve the beneficial effects of the combination therapy to enhance glucose control and may support this combination therapy in clinical practice [81]
Klinic supports your journey toward weight loss with present solutions and balanced, personalized plans
Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study